Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2025P A Herzen Journal of Oncology

Refractory/relapsed primary mediastinal large B-cell lymphoma: a changing paradigm for drug therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

МВМ. А. ВернюкАЧА. М. ЧервонцеваИЧИ. В. Черкашина

Discussion

Loading...

Member takes

Overview

Improved efficacy of new therapies, including CAR-T cell treatments, highlights significant shifts in management of PMBCL.

Key Points

  • About 10% of large b-cell lymphomas are primary mediastinal large B-cell lymphoma, with a portion becoming refractory or relapsed.
  • High-dose consolidation with autologous stem cell transplantation is a common salvage therapy approach when tumors are chemosensitive.
  • Molecular genetic understanding is paving the way for new therapies like immune checkpoint inhibitors and CAR-T cell therapies.
  • Despite advancements, the rarity of PMBCL still hinders the conduct of randomized trials to refine treatment strategies.

Cite This Study

Вернюк et al. (2025) studied this question.

synapsesocial.com/papers/68af35e9cf1dd9ea359ea4fahttps://doi.org/10.17116/onkolog202514041107
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Large B‐cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow‐up2025
  2. 2Pembrolizumab as an Unconventional First-line Salvage Therapy in Primary Mediastinal Large B-cell Lymphoma: A Case Report2025
  3. 3primary mediastinal B-cell lymphoma: Survival trends and statistics2025
  4. 4Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis2025 · 1 citations
  5. 5CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis.2025 · 7 citations